VA Healthcare System: GSA Award

The ExoDx Prostate Test is now available to US Veteran men.  The ExoDx Prostate test is a simple, non-invasive  urine test to assess a man's risk of having clinically significant prostate cancer. The ExoDx Prostate test does not require a digital rectal exam (DRE) and provides an individualized risk score that can help determine if prostate biopsy is warranted.  Watch how ExoDx Prostate fits into Clinical Practice, with Dr. Judd Moul! View the on-demand presentation or download the document below.

Exosome Diagnostics is pleased to announce that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI)  test for men. The decision is effective March 15th and will be available to more than 140 government entities including the VA Healthcare system, military branches such as Army, Navy, Air Force, Marines, as well as the U.S. Senate and House of Representatives and others. Now, approximately 9 million additional men will have access to this non-invasive test for early detection of prostate cancer.

The EPI test is a urine-based, genomic test that helps inform the prostate biopsy decision. This liquid biopsy test recently received FDA Breakthrough Designation and is included in the NCCN guidelines for early detection in men for both initial and repeat biopsy. It is performed by Exosome Diagnostics, a Bio-Techne brand, in its CLIA, ISO, NY certified and CAP-accredited laboratory located in Waltham, Massachusetts. The EPI test is a risk assessment tool that assists physicians and their patients with determining if a prostate biopsy is needed when presented with an ambiguous PSA test result, thereby reducing complications from unnecessary and invasive procedures.